Crewe Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Crewe Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-102	Closed	-$10.9K	–	883
2023 Q1	$10.9K	Hold	102	–	–	﹤0.01%	533
2022 Q4	$12.5K	Hold	102	–	–	﹤0.01%	515
2022 Q3	$11K	Hold	102	–	–	﹤0.01%	624
2022 Q2	$9K	Buy	+102	New	+$9.61K	﹤0.01%	610

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Crewe Advisors's ASND Position: Q2 2023 in Review

Crewe Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2023, closing a stake of 102 shares — an estimated $10.9K sold.

Crewe Advisors first reported a position in ASND in Q2 2022 and held it in 4 quarters. The position peaked at $12.5K in Q4 2022. 158 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

Crewe Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 102 Ascendis Pharma A/S shares in Q2 2023, an estimated $10.9K.
Crewe Advisors first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Ascendis Pharma A/S position peaked at $12.5K in Q4 2022.
158 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.